Jason Brown

Company: Everest Medicines

Job title: Chief Business Officer

Seminars:

4:15 PM Development of EVER001, a Covalent Reversible Bruton’s Tyrosine Kinase (BTK) Inhibitor, for the Treatment of Primary Membranous Nephropathy and Other Rare Kidney Diseases 4:15 pm

Outlining the role of BTK in modulating B-cell pathways that are involved in the pathogenesis of autoimmune kidney diseases Reviewing the current clinical data demonstrating the activity of EVER001 in primary membranous nephropathy Looking towards expanded applications in additional rare, immune-mediated kidney disordersRead more

day: Conference Day 1

2:30 PM Panel Discussion and Q&A: Navigating Global Partnerships, Funding Strategies & Value Demonstration in the Rare & Genetic Kidney Disease Field

Delving into challenges and best practices for safeguarding intellectual property during global collaboration efforts in the development and commercialization of therapies for renal disease Discussing innovative funding models, partnership strategies and approaches to attract investment in a competitive landscape Evaluating strategies for fostering partnerships and expanding clinical trials and market access in Asia Read more

day: Conference Day 2